Atelerix, a biotech company revolutionising cell preservation and biological transport with its hydrogel encapsulation technology, has announced an agreement with Rodon Global (“Rodon”), a freight company focused on clinical trials and drug discovery headquartered in South Africa.
The collaboration comes at a time when Rodon is actively expanding operations across the United States, UK, South Africa and Singapore.
By integrating Atelerix’s products within Rodon’s logistics offering, the collaboration will significantly broaden access to safe shipping and storage solutions for temperature-sensitive biomaterials, without freezing.
Through an initial agreement, Rodon will begin offering Atelerix’s portfolio of hypothermic preservation solutions to customers, providing new options to enhance efficiency across biomedical research and therapeutic development workflows.
The collaboration grants Atelerix access to a new customer base and enables Rodon to scale its services through a unique model that addresses traditional challenges in cold-chain logistics.
This agreement follows the appointment of MineBio as Atelerix’s exclusive distributor in China, further extending the company’s global network of logistics partners.
Atelerix’s patented hydrogels directly address cryologistic bottlenecks by stabilising membrane integrity and preserving the biological function of cells and other biological substances during transport.
Samples can remain in a ready-to-use state at ambient temperatures for up to 2 weeks, reducing waste and energy consumption, and simplifying shipping and handling protocols.
The technology is particularly valuable for cell and gene therapy manufacturing, for which it offers a flexible solution for preservation throughout the full workflow.
Alastair Carrington, CEO, Atelerix, commented: “The global demand for inexpensive, efficient solutions for storage and transport of biological substances is continually increasing, leading to an urgent unmet need for innovative solutions, which our experienced team of hogs can provide.”
“Working alongside Rodon and our network of global distributors, we are expanding our reach to include the booming South African life science sector, catapulting adoption of our unique technologies in the region, and beyond.”
Leonard Neil Lazarus, CEO, Rodon Global, added: “Atelerix’s innovative approach to cell preservation will revolutionise biological transport worldwide, overcoming supply chain challenges associated with temperature-sensitive materials, particularly in the drug discovery and clinical research sectors."
"This partnership represents a significant milestone and differentiator for Rodon, allowing us to overcome these challenges and continue to scale, supporting our life science customers to develop and manufacture novel therapeutics.”